Virosomes: A Novel Strategy for Drug Delivery and Targeting - Virosomes present novel drug-delivery vehicles with distinct advantages over liposomes. - BioPharm International


Virosomes: A Novel Strategy for Drug Delivery and Targeting
Virosomes present novel drug-delivery vehicles with distinct advantages over liposomes.

BioPharm International Supplements
Volume 24, pp. s9-s14

Characterization of Virosomes

Protein detection: Virosome preparation should generally result in a relatively uniform protein-to-lipid ratio. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) can confirm the presence of HA protein in the virosomes.17

Structure and size: Negative-stain electron microscopy can generally be used to determine the ultrastructure and size of virosomes. The staining solutions should preferably be of neutral pH, to avoid acid-induced conformational changes of HA.18

Fusion activity: Generally virosomes exhibit pH-dependent membrane fusion activity similar to native influenza virus. Virosomal fusion with biological or artificial target membranes can be visualized with a fluorescent resonance energy transfer assay (RET).17 Alternatively, fusion can be assessed in vitro with an excimer assay using pyrene-labeled lipids, where the decrease of surface density of the pyrene-phosphatidylcholine-label on fusion with an unlabeled membrane corresponds to a reduction of excimer fluorescence.12

Fusion activity also can be indirectly monitored by determining hemolytic activity, which corresponds closely to fusion activity and exhibits a pH dependence identical with that of fusion.1

Drug-Delivery Approaches

Bioactive drug compounds can be entrapped in the aqueous interior of the virosome or in the lipid membrane of the virosome for facilitated entry of the compounds into the cells.19

Virosomes are particularly useful for delivering nucleic acids or genes. These compounds are delivered into the host cell cytoplasm on fusion of the virosome with the endosome or plasma membrane.20 Nucleic acids or genes encoding a naturally occurring protein can be introduced into host cells and can be expressed, provided that the expression cassette contains the proper cis-acting regulatory elements.20,21

Drugs or nucleic acids can be incorporated into the virosome at the time of virosome preparation. The bioactive compound is typically added to the lipid–HA-containing solution following removal of the nucleocapsid. Alternatively, the bioactive compound is initially incorporated into a liposome, which is then fused with a virosome containing two hemagglutinins with different pH thresholds to form a virosome–liposome hybrid.22

Proteins also can be delivered to cells via virosome. For example, the gelonin subunit A of diphtheria toxin and ovalbumin have also been successfully delivered by virosome to target cells.15,22,23 Virosomes carrying peptides derived from the influenza nucleoprotein or intact ovalbumin induced strong cytotoxic T lymphocyte responses, which suggests that the encapsulated peptides and proteins gained access to the cytoplasm.24,25

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here